Key Highlights:
- Independent medical experts are conducting a joint review of Philadelphia Eagles quarterback Jalen Hurts’ blood clot diagnosis to share findings with the NFL and the NFL Players Association.
- Hurts was initially diagnosed in London with a superficial blood clot before advanced testing revealed deep vein thrombosis (DVT) and pulmonary emboli in both lungs.
- The quarterback is clinically stable and receiving anticoagulant therapy, which bars him from contact activities until he receives formal medical clearance.
NFL and NFLPA Commission Independent Medical Review
Independent medical specialists are reviewing the circumstances surrounding Philadelphia Eagles quarterback Jalen Hurts’ recent blood clot diagnosis. The findings of this evaluation will be formally presented to both the NFL and the NFL Players Association (NFLPA). Officials have confirmed that the joint inquiry is not a disciplinary investigation, and no formal findings or conclusions have been released. Instead, the initiative is designed to assess the care provided and help both the league and the players’ union determine whether current protocols warrant revised medical guidance regarding vascular conditions.
Medical Timeline: From Calf Trauma to Pulmonary Emboli
The diagnosis originated around the team’s international travel. According to the Philadelphia Eagles, Jalen Hurts was initially diagnosed in London with a superficial blood clot located in his left calf. Prior to traveling across the Atlantic, Hurts reported being cleated in the calf during a contest against the Los Angeles Rams. He subsequently traveled overseas and played against the Jacksonville Jaguars. Following further diagnostic evaluation and ongoing clinical monitoring, his condition was updated to deep vein thrombosis (DVT) accompanied by pulmonary emboli affecting both lungs.
A superficial blood clot develops in veins situated near the surface of the skin, whereas deep vein thrombosis forms within deeper venous structures, most commonly in the legs. A pulmonary embolism arises when a displaced clot travels through the bloodstream and obstructs an artery within the lungs, creating a potentially life-threatening complication. While leg clots are routinely evaluated via ultrasound, pulmonary embolisms typically require computed tomography (CT) scans for definitive detection.
Treatment Protocols and Athletic Participation Risks
The Philadelphia Eagles and Jalen Hurts’ representative confirmed that the quarterback remains clinically stable and is experiencing no significant functional limitations. His current therapeutic regimen involves anticoagulants, commonly referred to as blood thinners. These medications prevent existing clots from enlarging and inhibit the formation of new blockages while the body naturally breaks down and reabsorbs the clot burden over time.
Because blood thinners significantly increase bleeding risks following blunt trauma, the Eagles stated that Hurts will strictly avoid all contact sports activities while undergoing anticoagulant therapy. Although the franchise characterized his overall medical prognosis as very good, any eventual return to NFL action remains entirely contingent upon comprehensive medical clearance once the treatment course concludes.
Precedents Across the League: Historical Cases of NFL Blood Clots
Jalen Hurts is not the first high-profile professional football player to navigate a serious vascular issue during an active playing career. In 2019, New England Patriots center David Andrews was diagnosed with pulmonary emboli in his lungs, which forced him to miss the entirety of that campaign; Andrews successfully returned to the field for the 2020 season before eventually retiring in 2025. That same year, Los Angeles Chargers offensive tackle Russell Okung experienced a pulmonary embolism, sat out the first seven weeks of the season, and was cleared to return later that year.
By contrast, former Cincinnati Bengals offensive guard Clint Boling announced his retirement from professional football in 2019 following eight seasons after medical personnel determined that continuing to play with a blood clot in his leg posed excessive health risks. Medical professionals emphasize that because each patient’s clinical circumstances, underlying biology, and hematological risk factors differ, these past outcomes cannot serve as a direct roadmap for Hurts’ recovery trajectory or return to competition.
Why This Matters
The joint examination by independent medical specialists carries notable implications for professional sports medicine and player safety standards. Physical fitness, youth, and elite athletic conditioning do not grant immunity from vascular disorders, and diagnosing these conditions can be complicated when symptoms mirror ordinary musculoskeletal football injuries like deep muscle contusions. Although reports documented that Hurts suffered a cleat strike to his calf, no public medical determination has verified that the physical blow, international air travel, or his participation in the London game directly caused the condition. The upcoming expert report could establish clearer diagnostic timelines and prompt the NFL and NFLPA to introduce standardized screening protocols for deep vein thrombosis across all 32 franchises.
Frequently Asked Questions
What medical conditions was Jalen Hurts diagnosed with?
Jalen Hurts was initially diagnosed in London with a superficial blood clot in his left calf. Subsequent medical testing and monitoring revealed that the condition had progressed to deep vein thrombosis (DVT) along with pulmonary emboli in both lungs.
Is the joint review an investigation into disciplinary wrongdoing?
No. The joint review conducted by independent medical experts for the NFL and NFLPA has not been characterized as a disciplinary investigation. Its primary objective is to review the diagnosis and medical care provided to determine whether existing league policies and medical guidance regarding blood clots require updates.
When can Jalen Hurts play football again?
There is no public timetable for Jalen Hurts’ return to game action. The Philadelphia Eagles have stated that his prognosis is very good, but he cannot participate in any contact activities while taking prescribed anticoagulant medications. His return to the field depends entirely on medical clearance.



